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Objective. To identify biomarkers in the first
synovial fluid (SF) aspirate obtained from children with
oligoarticular juvenile idiopathic arthritis (JIA), which
could be used to identify children whose disease is likely
to extend to a more severe phenotype.
Methods. Patients with recent-onset oligoarticu-
lar JIA were identified and grouped according to those
whose mild disease persisted (persistent disease) or
those whose disease would extend from a mild to more
severe phenotype (extended-to-be disease) at 1 year
after diagnosis. Flow cytometry was used to delineate
differences in the mononuclear cell populations between
the first blood sample and first SF aspirate from the
same patient and between outcome (persistent versus
extended-to-be) groups. Proportions of lymphocytes in
the joint were modeled on chemotaxis of lymphocytes to
CCL5, using Transwell migration assays. Levels of
CCL5 in the SF were quantified by enzyme-linked
immunosorbent assay. RNA profiles of SF mononuclear
cells were compared between groups using the Af-
fymetrix GeneChip hybridization protocol and hierar-
chical clustering analyses.
Results. Compared with peripheral blood mono-
nuclear cells, SF mononuclear cells displayed an expan-
sion of CD8 T cells, reduced proportion of B cells, and
expansion of CD16 natural killer cells. The lower
CD4:CD8 ratio in the SF was recapitulated in vitro by
the observed migration of blood T cells in response to
CCL5. Synovial CCL5 levels were higher in children
whose disease extended to a more severe phenotype. The
CD4:CD8 ratio in the SF was significantly lower in
patients with extended-to-be oligoarticular JIA (0.57
compared with 0.90 in the persistent disease group,
difference 0.33, 95% confidence interval 0.04–0.62; P 
0.009). Gene expression profiling revealed that 344
genes were >1.5-fold differentially expressed between
outcome groups (P < 0.05), and these included genes
associated with inflammation and macrophage differen-
tiation, which showed increased levels in patients with
extended disease at 1 year, and genes associated with
immune regulation, which showed increased levels in
patients with persistent disease at 1 year.
Conclusion. Analyses of the proportions of syno-
vial lymphocytes, levels of CCL5, and differential gene
expression yielded potential biomarkers with which to
predict the likelihood of extension of oligoarticular JIA
to a more severe disease phenotype.
Inflammatory arthritis in children presents with a
diverse range of phenotypes, of which the most common
is arthritis that starts in 4 joints, known as oligoarticu-
lar juvenile idiopathic arthritis (JIA) (1). Although
sometimes thought of as a benign condition, oligoarticu-
lar JIA may, in fact, lead to a wide spectrum of out-
comes, ranging from complete remission after discontin-
uation of medication to development of a severe,
extended form of JIA that spreads to involve many joints
(5 joints). Extended oligoarticular JIA can be highly
erosive and destructive and may be difficult to control
with conventional disease-modifying antirheumatic
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896drugs (DMARDs), thus requiring long-term treatment
with biologic therapies. When oligoarticular JIA remains
limited to 4 joints, so-called persistent oligoarticular JIA,
it is typically relatively easy to control with local intraartic-
ular steroids and nonsteroidal medication (2,3).
A large study of remission rates in different
subtypes of JIA found that after 4 years of followup,
only 31% of children with extended oligoarticular JIA
achieved remission after discontinuing their medication,
compared with 68% of those with persistent oligoarticu-
lar JIA (4). In a long-term retrospective outcome study
in adults who had previously been diagnosed as having
JIA, those with extended oligoarticular JIA had signifi-
cantly worse Health Assessment Questionnaire physical
function scores than those whose disease had remained
persistent (in 4 joints) (5). Extension of the disease to
5 joints in this form of childhood arthritis has been
reported to occur in as high as 50% of patients at 5 years
and carries a far higher risk of chronic disability (6).
Several clinical factors have been proposed as predictors
of extension, such as a high erythrocyte sedimentation
rate (ESR), upper-limb involvement, and involvement of
1 joint or symmetric joint involvement at presentation
(6,7). Currently, no simple clinical algorithm can be
applied to predict extension, but meeting this need
would represent a major step forward in the care of
children with arthritis.
We have previously shown that once extension of
the disease to many joints has occurred, these 2 subtypes
of oligoarticular JIA have significantly different immu-
nologic characteristics in the synovial infiltrate. Thus, we
demonstrated that the proinflammatory T cell subset
that produces interleukin-17 (IL-17), IL-21, and IL-22
(the Th17 subset) is enriched in the joints, compared
with the blood, of children with JIA, and that this cell
type is found in significantly higher numbers in the joints
of children with extended oligoarticular JIA than in
those with persistent oligoarticular JIA (8). In contrast,
we and others have shown that immunoregulatory T
cells (known as Treg cells), which express high levels of
CD25 (IL-2 receptor ) and the transcription factor
FoxP3, are present at significantly higher numbers in the
joints of children with persistent oligoarticular JIA than
in those with extended disease (9,10). Interestingly, we
also found that these 2 specific T cell subpopulations
show a directly reciprocal relationship within the joint (8).
In addition to these cellular correlates, there are
significant genetic differences between these 2 subtypes
of JIA. Within the HLA region, which codes for multiple
genes critical to immune function, the haplotype HLA–
DRB1*0801/DQA1*0401/DQB1*0402 is associated with
both persistent and extended oligoarticular JIA, al-
though the effect size is greater within the extended
disease subgroup, while the HLA–DRB1*1301/
DQA1*01/DQB1*06 haplotype confers an increased
risk of persistent, but not extended, oligoarticular JIA
(11). Similarly, an IL-10 promoter polymorphism that is
associated with low IL-10 production (ATA haplotype)
has been found to be significantly associated with ex-
tended oligoarticular JIA (12).
Given these cellular and genetic associations that
are relatively specific for these 2 subtypes of JIA, we
reasoned that there may be differences in molecular or
cellular features within the inflamed joint that occur
early in oligoarticular JIA and that could be predictive of
extension from mild to a more severe disease. Once
these differences are identified, they might form the
basis of a diagnostic test, which, combined with clinical
features, might be used to generate an algorithm allow-
ing selection of those children who would need more
frequent followup and might require early intervention
with DMARDs. Previous studies using gene expression
profiling in JIA have focused upon polyarticular disease
(13) or have not distinguished between persistent and
extended oligoarticular JIA (14). To our knowledge, no
previous study has specifically chosen to identify predic-
tors of disease extension, before it occurs, with the use of
transcriptome analyses. Such an approach to the devel-
opment of predictive biomarkers has been highly suc-
cessful in other fields, notably, oncology (15,16).
In the present study, we therefore tested the
hypothesis that synovial fluid (SF) cellular composition,
gene expression, and/or cytokine and chemokine profiles
could reveal significant differences that might be predic-
tive of the extension of oligoarticular JIA before it
occurs. We used SF samples obtained at the first thera-
peutic aspiration and before use of DMARDs, and we
chose early disease extension (within 1 year after diag-
nosis) as the end point. Of note, we have opted to use
the term extended-to-be for those children who were
studied at a time when the disease was still limited to 4
joints but whose oligoarthritis had extended to a more
severe phenotype by 1 year of followup.
PATIENTS AND METHODS
Patients and samples. Samples from a total of 38
children (26 female and 12 male) who met the International
League of Associations for Rheumatology criteria for oligoar-
ticular JIA (1) and 6 healthy children as controls were included
in this study. Patients attended either Great Ormond Street
Hospital, London, or the Royal Victoria Infirmary, Newcastle,
UK, the latter as part of the Childhood Arthritis Prospective
BIOMARKERS OF EXTENDED OLIGOARTICULAR JIA 897Study (CAPS) (17). The study received approval from the local
ethics review committee and the multicenter ethics review
committee. Full informed consent was obtained from the
parents of each child.
The 38 patients with oligoarticular JIA in this study
had a mean age of 8.8 years (range 1.3–13 years) and median
disease duration of 7 months (range 2–16 months). All 38
children were undergoing their first knee aspiration of SF,
which was clinically indicated in order to receive an intraartic-
ular injection of triamcinolone hexacetonide, and none of the
children had yet received methotrexate, steroids, or any other
DMARD. SF samples were obtained at the time of clinically
indicated arthrocentesis and, where available, samples of peri-
pheral blood (PB) were collected at the same time. Samples
were processed within 1 hour of removal from the patient.
PB mononuclear cells (PBMCs) were isolated with
density centrifugation using Lymphoprep (Axis-Shield, Oslo,
Norway). For preparation of SF mononuclear cells (SFMCs),
samples were first treated with 10 units/ml hyaluronidase
(Sigma, Poole, UK) for 30 minutes at 37°C, before isolation
with Lymphoprep density centrifugation. For some patients,
samples of plasma or SF were also obtained for the analysis of
cytokines and chemokines. These samples were spun to re-
move cells, and were frozen at 80°C within 1 hour after
removal from patients.
Analysis by flow cytometry. Standard 5-color flow
cytometry was performed for surface markers using directly
labeled monoclonal antibodies against the following human
proteins: CD3–phycoerythrin (PE)-Cy7 (UCHT1; Southern
Biotechnology, Birmingham, AL), CD3–allophycocyanin
(APC) (S4.1; Caltag, Burlingame, CA), CD4–peridinin chlo-
rophyll A protein (PerCP) (L200; BD Biosciences, San Diego,
CA), CD4-APC (S3.5; Southern Biotechnology), CD8–
fluorescein isothiocyanate (FITC) (G42-8; BD Biosciences),
CD8-PE (DK25; Dako, Glostrup, Denmark), CD8–PE-Cy7
(RPA-T8; BD Biosciences), CD8-APC (RTF8; Southern Bio-
technology), CD13-APC (WM15; BioLegend, San Diego, CA),
CD14-PerCP (P9; BD Biosciences), CD16–PerCP-Cy5.5
(3G8; BD Biosciences), CD19-FITC (HIB19; BD Bio-
sciences), CD25-PE (ACT-1; Dako), CD25–PE-Cy5 (M-A251;
BD Biosciences), CD56-PE (B159; BD Biosciences),
CD195-PE (2D7/CCR5; BD Biosciences), and T cell receptor
/–FITC (11F2; BD Biosciences).
The following intracellular proteins were detected by
flow cytometry, following fixation and permeabilization of the
cells: FoxP3-APC (PCH101; eBioscience, San Diego, CA),
Ki-67–FITC (B56; BD Biosciences), and IL-17–Alexa Fluor
647 (64CAP17; eBioscience). For detection of FoxP3, buffers
from the FoxP3 Staining Set (eBioscience) were used. For
detection of Ki-67 and IL-17, cells were fixed with 4% para-
formaldehyde (BDH Chemicals, Poole, UK) in phosphate
buffered saline (PBS) (Sigma) and permeabilized with 0.1%
saponin in PBS containing 1% fetal calf serum (Invitrogen,
Renfrew, UK) and 0.1% sodium azide (Sigma). For analysis of
IL-17 production by T cells, the SFMCs or PBMCs were
cultured for 3 hours in the presence of 50 ng/ml of phorbol
myristate acetate (Sigma), 500 ng/ml of ionomycin (Sigma),
and 5 g/ml of brefeldin A (Sigma), before analysis by
intracellular staining and flow cytometry as described above.
Levels of apoptosis in cell populations were estimated
by detecting active caspases using the Vybrant FAM Poly
Caspase Assay Kit (Molecular Probes, Eugene, OR). VAD
(Val-Ala-Asp) binds to the groove in most caspases (including
caspase 1 and caspases 3 through 9), and these are exposed by
cleavage to their active forms (18). The FLICA reagent
combines VAD with FMK to create a covalent link with the
target caspase, and FAM is used for fluorescence detection.
Cells were resuspended in RPMI 1640 (Invitrogen) at 1 
10
6/ml, incubated at 37°C in 5% CO2 for 1 hour with FLICA
reagent, washed with the kit buffer, and stained for CD3, CD4,
and CD8. PBMCs that had been stimulated with anti-CD3/
anti-CD28 beads (Miltenyi Biotech, Bergisch Gladbach, Ger-
many) for 4 days followed by 20-hour treatment with brefeldin
A (Sigma) were used as a positive control for caspase activity.
Flow cytometric data were collected on an LSRII (BD
Biosciences) or Cyan ADP (Beckman Coulter, Fullerton, CA);
from 100,000 to 200,000 events were collected for each condi-
tion, and cells were gated according to scatter properties. Flow
cytometric data were analyzed using FlowJo software (Tree-
Star, Ashland, OR).
Enzyme-linked immunosorbent assay (ELISA). Detec-
tion of CCL5 in the plasma and SF was performed using an
ELISA (R&D Systems, Abingdon, UK) according to the
manufacturer’s instructions.
Chemotaxis assay. PBMCs were allowed to adhere to
plastic for 3 hours at 37°C in 5% CO2 in RPMI/5% human AB
serum in order to deplete monocytes and enrich for lympho-
cytes. Nonadherent cells at a starting concentration of 5 
10
6/ml were exposed to 20–500 ng/ml CCL5 (R&D Systems) in
RPMI/0.5% bovine serum albumin (BSA) or RPMI/0.5% BSA
alone in the lower chamber of a 5-m–pore, polycarbonate-
filter Transwell chamber (Corning Life Sciences, Schiphol-
Rijk, The Netherlands). After 90 minutes, migrated cells were
recovered and stained with anti-human CD3, CD8, and CD4
antibodies. Immediately prior to analysis of the data by flow
cytometry, 20,000 fluorescence-activated cell sorter counting
beads (Perfect Count; Cytognos, Salamanca, Spain) were
added per sample. The numbers of cells detected per sample
were standardized relative to the bead numbers.
Gene expression profiling. SFMCs were thawed and
total RNA was prepared from 2–5  10
6 cells using RNeasy
spin columns (Qiagen, Hilden, Germany). The quality and
purity of the RNA was assessed using a Bioanalyzer 2100
(Agilent Technologies, Palo Alto, CA). Complementary DNA
and subsequent complementary RNA (cRNA) synthesis was
then performed as previously described (19). Purified cRNA
transcripts were fragmented and hybridized to human U133
plus 2.0 GeneChips according to Affymetrix standard proto-
cols (see http://www.affymetrix.com). Signal values were calcu-
lated using MAS 5.0, with results scaled to 100 and normalized
to the median value, prior to analysis with GeneSpring GX 10
software (Agilent Technologies). Probe sets were excluded if
the signal strength did not significantly exceed background
values and if expression did not reach a threshold value for
reliable detection (based on the relaxed Affymetrix MAS 5.0
probability of detection; P  0.1 [20]) in 5 of 21 samples.
A list of probe sets in which the difference in mean
expression levels between the 2 patient groups was more than
1.5-fold was statistically analyzed by the Student’s t-test with
Welch’s correction, and a P value cutoff of 0.05 was applied for
the level of significance. Functional categories for correspond-
ing genes were assigned using gene ontology terms from the
898 HUNTER ET ALGene Ontology Consortium (see www.geneontology.com). Hi-
erarchical clustering was performed using average linkage.
Complete gene expression data for each patient are available
on the GEO database (GEO accession no. GSE15083; www.
ncbi.nlm.nih.gov).
Statistical analysis. All analyses of the data, including
logistic regression models, were performed in SPSS version 15
(SPSS, Chicago, IL). P values less than 0.05 were considered
significant.
RESULTS
Clinical characteristics. In this study of the first
joint aspirate obtained from children with oligoarticular
JIA, we defined the composition of the mononuclear cell
populations in the SF compared with the PB. We then
Figure 1. Differences in mononuclear cell subsets in the synovial fluid compared with peripheral blood of children with oligoarticular juvenile
idiopathic arthritis. Flow cytometry was used to enumerate proportions of A, T cells versus B cells from the live cell gate, B, CD4 and CD8
T cell subsets from the CD3 live cell gate, as well as T cell receptor /–bearing (TCR) cells detected with a specific antibody, and C,
natural killer cell subsets from the CD56 live cell gate. Representative results are shown, in flow cytometry plots (left) and quantitatively
as the mean  SD proportion of each cell subset in 14 paired patient samples (right).
Table 1. Clinical characteristics of the patients with known outcome
at 1 year*
Outcome
Persistent
oligoarticular
JIA (n 	 21)
Extended-to-be
oligoarticular
JIA (n 	 11)
Female, no. (%) 14 (67) 8 (73)
Age at sampling, mean  SD
years
6.8  3.7 5.1  3.5
Disease duration, mean  SD
months
7.4  3.7 8.1  3.9
Erythrocyte sedimentation rate,
mean  SD mm/hour
21  17 29  23
Receiving MTX or prednisolone
prior to or at the time of
sampling, no.
00
* JIA 	 juvenile idiopathic arthritis; MTX 	 methotrexate.
BIOMARKERS OF EXTENDED OLIGOARTICULAR JIA 899looked for demonstrable differences in SFMC composi-
tion in children whose arthritis would remain mild
(persistent oligoarticular JIA) compared with those
whose disease would extend to a more severe phenotype
(extended-to-be oligoarticular JIA) at 1 year after diag-
nosis. At the time of sampling, there were no significant
differences in the clinical characteristics between these 2
outcome groups (Table 1).
Differences in composition of mononuclear cells
in the synovial exudate compared with the peripheral
blood in children with oligoarticular JIA. Flow cytom-
etry was used to compare the proportions of mono-
nuclear cell subsets between the PB and aspirated SF
from children with oligoarticular JIA. The most promi-
nent differences were observed in the paucity of B cells
in the SF (mean  SD 1.8  1.3% versus 14.5  4.8% in
the blood) (Figure 1A) and the predominance of CD8 T
cells in the SF (Figure 1B), so that there was a reversal
of the typical CD4:CD8 T cell ratio observed in the
blood of these children (21). Within the natural killer
(NK) cell subset, identified as expressing CD56, we
observed a preponderance of CD16 cells in the SF
(Figure 1C). The majority of blood-borne NK cells
express the Fc receptor. The down-regulation of CD16
Figure 2. Differences in the proportions of synovial fluid mononuclear cell (SFMC) subsets in patients with persistent oligoarticular juvenile
idiopathic arthritis (JIA) (n 	 21) compared with those with extended-to-be oligoarticular JIA (n 	 11), and the utility of these measures as
predictors of outcome. A, Proportions of T cell, B cell, monocyte/macrophage (CD14), and total myeloid cell (CD13) subsets, derived from
flow cytometry, in patients with persistent oligoarticular JIA (light gray bars) compared with patients with extended-to-be disease (dark gray
bars). Results are the mean  SEM percentage relative to that of total live cells. B, CD4:CD8 T cell ratios, derived from flow cytometry, in
patients with persistent versus extended-to-be oligoarticular JIA. Circles indicate individual samples; horizontal lines indicate the median. C,
Probability of disease extension in a logistic regression model using the proportions of CD4 and CD19 lymphocytes to predict the outcome,
which was correctly predicted in 27 (84%) of 32 patients. Circles indicate individual patients; horizontal lines indicate the median. D, Receiver
operating characteristic curves comparing the CD4:CD8 ratio (area under the curve 0.79) with the CD4 T cell–B cell model derived from logistic
regression (area under the curve 0.90).  	 P  0.05;  	 P  0.01;  	 P  0.001, between outcome groups, by Mann-Whitney U test.
900 HUNTER ET ALon NK cells in an inflamed site has been previously
described in patients with rheumatoid arthritis (RA) (22).
Correlation of reversal of the CD4:CD8 ratio in
synovial T cells early in disease with likelihood of
progression to a more severe disease phenotype. We
compared the proportions of SF T cell, B cell, NK cell,
monocyte/macrophage, and dendritic cell subsets be-
tween the patient group whose disease had remained
persistent (mild disease in 5 joints) (n 	 21) and those
whose disease had extended to 5 joints (n 	 11) at 1
year after diagnosis. A statistically significant difference
was observed in the proportion of the total SFMCs that
were CD4 T cells (Figure 2A). While both groups had
the same proportion of SF T cells overall (Figure 2A),
the CD4:CD8 ratio was lower in the group with ex-
tended disease at 1 year (difference 0.33, 95% confi-
Figure 3. Measures of proliferation, apoptosis, and migration of T cell subsets in the synovial fluid (SF) of patients
with oligoarticular juvenile idiopathic arthritis. A–C, SF (n 	 12) (A and B) and peripheral blood (n 	 7) (C) CD4
and CD8 T cells were compared for A, intracellular expression of Ki-67, B, binding of VAD tripeptide to active
caspases, and C, surface expression of CCR5 as determined by flow cytometry gated on live, CD3 cells. D, The
levels of CCL5 (RANTES) in the SF (n 	 10 with persistent disease, n 	 5 with extended-to-be disease) were
measured by enzyme-linked immunosorbent assay. Circles indicate individual patients; horizontal lines indicate the
median. E, SF levels of CCL5 were compared with CD8 T cell levels as a percentage of the total live SF
mononuclear cells (SFMC) from 14 patients (r
2 	 0.13, P 	 0.21). F, Migration to CCL5 lowers the CD4:CD8 ratio,
as determined in a Transwell assay using nonadherent peripheral blood mononuclear cells from healthy adults. Bars
show the mean  SD results from 3 individual samples.  	 P  0.01 by Mann-Whitney U test.
BIOMARKERS OF EXTENDED OLIGOARTICULAR JIA 901dence interval [95% CI] 0.038–0.62; P 	 0.009) (Figure
2B).
Since the CD4:CD8 ratio is a simple laboratory
measure that can be routinely applied, we considered its
merit as a predictive test for the likelihood of extension
of oligoarticular JIA. Using a receiver operating charac-
teristic curve, a ratio of 0.67 was established as the
optimal cutoff value for maximizing the sensitivity and
specificity of the test (Figure 2D). Thus, in our data set,
a patient with a CD4:CD8 ratio of lower than 0.67 was
2.5 times more likely (95% CI 1.16–5.4) to experience
disease extension to a more severe phenotype.
Joint cell proportions further increased the pre-
dictive power in a logistic regression model that used B
cell percentages in addition to CD4 T cell subset per-
centages. The proportion of B cells was higher, but not
significantly higher, in the group with extended disease
compared with the group with persistent disease at 1
year (Figure 2A). However, the regression model that
combined B cell and CD4 T cell proportions correctly
assigned 27 (84%) of 32 patients (Figure 2C). Factoring
in the proportions of other cell subsets, including the
CD8 T cell proportions, improved the accuracy of
prediction, but these did not contribute significantly (at
a level of P  0.05) to the model. In a separate
regression analysis, the clinical parameters of age, dis-
ease duration, ESR, and joint count at the time of
sampling neither improved the model nor were predic-
tive of the outcome. (The equation used to calculate the
probability of disease extension using the CD4 T cell/B
cell model is available from the corresponding author
upon request).
We have previously shown that once disease
extension occurs, there are significant differences in the
proportions of both Treg cells and Th17 cells in the joint
(8,9). We therefore examined the Treg cell
(FoxP3CD4) and IL-17CD4 T cell subsets in the
2 disease outcome groups. Neither the proportion of
Treg cells nor the proportion of Th17 cells, measured at
presentation, was predictive of disease extension, al-
though the reciprocal relationship between the numbers
of these 2 cell types was maintained (see Supplementary
Figure 1, available on the Arthritis & Rheumatism Web
site at http://www3.interscience.wiley.com/journal/
76509746/home).
Matched rates of cell turnover between synovial
CD4 and CD8 T cells. Since we were able to establish the
predominance of CD8 T cells in the joint and its
implications in predicting the disease course in children
with oligoarticular JIA, we wanted to investigate the
cellular dynamics that are potentially driving CD8 T cell
accumulation. We hypothesized that CD8 T cells might
be expanding through proliferation or undergoing apo-
ptosis to a lesser extent compared with CD4 T cells.
Ki-67 is an antigen that is expressed during the S and M
phases of the cell cycle, and thus can be an indicator of
the fraction of the T cell population undergoing cell
division (23). No difference in the proportion of Ki-67
cells between CD4 T cells and CD8 T cells from the
same SFMC samples was observed (Figure 3A). Simi-
larly, we estimated apoptotic activity by detecting acti-
vated caspases using the VAD-FAM reagent. We ob-
served no significant difference in VAD cells between
CD4 SF T cells and CD8 SF T cells (Figure 3B).
Therefore, the observed dominance of CD8 T cells over
CD4 T cells in the joint could not be explained by
differences in cell death or proliferation.
Contribution of synovial chemokine migration to
the altered CD4:CD8 ratio within the joint. We consid-
ered mechanisms that might contribute to enrichment
for CD8 T cells through chemoattraction from the blood
to the inflamed joint. As shown in Figure 3C, CCR5/
CD195 was found to be expressed on a higher propor-
tion of CD8 T cells compared with CD4 T cells, similar
to observations in the blood of healthy adults and
children (24) as well as the results of our previous study
(25). We and others have described a role for CCL5
(RANTES), a ligand of CCR5, in JIA, and indeed, high
levels in the blood and SF have been reported to be a
predictor of disease flares (26,27). As shown in Figure
3D, the levels of CCL5 were found to be significantly
higher in the SF of patients in the extended-to-be
disease group compared with patients whose disease
remained persistent. The SF CCL5 levels showed a weak
correlation with SF CD8 T cell proportions (Figure
3E), suggesting that CCL5 could play a role in the
enrichment for CD8 T cells in the joint.
To test the effect of CCL5 on T cell migration in
vitro, nonadherent PBMCs from healthy adults were
exposed to increasing concentrations of CCL5 in a
Transwell assay. CCL5 was able to enrich for CD8 T
cells to a greater extent than that for CD4 T cells, thus
decreasing the CD4:CD8 ratio in a dose-dependent
manner (Figure 3F).
Differential SFMC gene expression in children
with extended-to-be disease. Microarray-generated gene
expression levels were obtained in 13 SFMC samples
from children with persistent disease and 8 SFMC
samples from those with extended-to-be disease. A total
of 362 probe sets covering 344 individual genes were at
least 1.5-fold differentially expressed at a significance
level of P  0.05 (for the annotated probe sets, see
902 HUNTER ET ALSupplementary Table 1, available on the Arthritis &
Rheumatism Web site at http://www3.interscience.
wiley.com/journal/76509746/home). The expression of
155 genes was increased and the expression of 189 genes
was decreased in patients with extended disease com-
pared with patients with persistent disease at 1 year.
Probe sets with more than 2-fold gene expression were
clustered, by average linkage analysis, along with each
outcome group (Figure 4).
Some of the differentially expressed genes asso-
ciated with immune function and inflammation are listed
in Table 2 (also labeled in Figure 4). In general, genes
Figure 4. Hierarchical clustering analysis of genes differentially expressed in synovial fluid mononuclear cells of
patients with persistent oligoarticular juvenile idiopathic arthritis (JIA) (n 	 13) compared with patients with
extended-to-be oligoarticular JIA (n 	 8). The heat map shows genes (as labeled to the right of the map) that were
2-fold differentially expressed at a significance level of P  0.05, as determined by Student’s t-test with Welch’s
correction. Each row represents a different probe set, and each column represents an individual patient sample. The
normalized expression level for each gene and each patient is indicated by colors, with red, yellow, and blue reflecting
expression levels greater than, equal to, or less than the mean value, respectively, for all of the patients. The boxes
below the cluster indicate patients whose disease persisted versus those whose disease had extended at 1 year after
diagnosis.
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tended to be more highly expressed in the extended-
to-be disease group, and genes associated with immune
regulation were more highly expressed in the persistent
disease group. One interesting exception was the in-
creased expression of RORC (retinoic acid–related or-
phan receptor C), a transcription factor involved in the
differentiation of proinflammatory IL-17–secreting cells
(28), in the persistent disease group.
A subset of genes that were more highly ex-
pressed in the extended-to-be disease group included
markers of macrophage differentiation to both M1
effector cell types (CXCL9, SLC31A2, ATF3) and M2
effector types (CCL18, fibronectin) (29). Several tran-
scripts of genes for components of the complement
pathway, also likely derived from macrophages, were
overrepresented in the extended-to-be disease group.
The proportion of monocyte/macrophages, as identified
by coexpression of CD13 and CD14 in the SFMC
samples, did not significantly differ between the persis-
tent and extended-to-be disease sample sets that were
subjected to microarray analysis or in the complete
patient groups (Figure 2A). Cartilage glycoprotein 39
(chitinase 3–like 1), which is found in the serum and
synovium of patients with RA and patients with osteo-
arthritis, shows a tendency to be correlated with disease
severity (30), and therefore, it was interesting to find
more of its transcript in the patients whose disease
extended to oligoarticular JIA in this study.
There was good agreement between gene expres-
sion and protein measurements for the CD8 antigen.
This antigen was more highly expressed in the extended-
to-be disease group, in whom there was also a higher
proportion of CD8 T cells. Similarly, higher levels of
interferon- (IFN) messenger RNA corresponded to a
trend toward proportionally more IFN in the SF of the
patients with extended-to-be disease, as detected by
Luminex assay (results not shown).
DISCUSSION
This study was performed to identify predictors
of the future worsening of disease in children with an
initially benign arthritis, by screening for molecules in
the affected joints. Our results revealed biomarker can-
didates with previously described roles in inflammatory
or regulatory processes, as well as novel factors whose
role in JIA are not yet clearly defined.
This report documents the dominance of CD8 T
cells in the joint and the corresponding reversal of the
CD4:CD8 ratio in the blood, which is typically a ratio of
between 1.5 and 3 in healthy individuals (31) but was 1
in the majority of analyzed SF samples from children
with oligoarticular JIA. In this study, the extent to which
Table 2. Genes differentially expressed in synovial fluid mononuclear
cells of patients with extended-to-be oligoarticular juvenile idiopathic
arthritis compared with those with persistent disease at 1 year after
diagnosis
Functional category, gene name Symbol
Fold
change*
Cell surface protein
Interferon-inducible 27 IFI27 4.2
Macrophage receptor with
collagenous structure
MARCO 3.1
Interleukin-31 receptor  IL31RA 2.7
T cell immunoglobulin and mucin
domain–containing 4
TIMD4 2.1
Interferon-–inducible protein IFI6 1.8
Solute carrier family 31, member 2 SCL31A2 1.7
CD8 CD8B1 1.6
CXCR6 CXCR6 1.6
Vasoactive intestinal peptide
receptor 1
VIPR1 1.7
Leukocyte-associated Ig-like
receptor 2
LAIR2 2.0
CXCR2 (interleukin-8 receptor ) IL8RB 2.3
CCR3 CCR3 2.7
Cytokine or chemokine
CCL18 CCL18 3.0
CXCL9 CXCL9 3.0
Interferon- IFNG 1.7
Small inducible cytokine subfamily
E1
SCYE1 1.5
Complement
C1q, C chain C1QC 4.0
C1q, B chain C1QB 3.5
C1q, A chain C1QA 3.1
C2 C2 3.2
Nuclear receptor or protein
Nuclear receptor subfamily 4,
group A2
NR4A2 2.3
Activating transcription factor 3 ATF3 1.9
Runt-related transcription factor 1 RUNX1 1.7
Retinoic acid–related orphan
receptor C
RORC 3.4
Cytoplasmic protein
Fatty acid binding protein 3 FABP3 2.3
Endoplasmic reticulum
aminopeptidase 2
ERAP2 2.2
Sma and Mad (Drosophila)–related
protein homolog 3
SMAD3 1.7
Extracellular mediator
Chitinase 3–like 1 (cartilage
glycoprotein 39)
CHI3L1 4.2
Fibronectin 1 FN1 2.8
Adiponectin ADIPOQ 2.5
-tryptase or -tryptase 1 TPSAB1 6.0
* Fold change is the ratio of the mean gene expression value in the
extended-to-be disease group to that in the persistent disease group.
Positive values denote higher expression in the extended-to-be disease
group, and negative values indicate higher expression in the persistent
disease group.
904 HUNTER ET ALthis reversal occurs in the joint is a predictor of unfavor-
able outcome. Determination of the CD4:CD8 ratio is a
simple procedure and could be easily adopted as a
prognostic test, if validated in a larger study group.
Logistic regression analyses of all mononuclear cell
types revealed that B cells, even in their reduced pro-
portions in the SF compared with that in the blood, can
also function prognostically and in a manner indepen-
dent of the CD4:CD8 ratio.
The predominance of CD8 T cells in the synovial
tissue of patients with JIA, and in the oligoarticular
subtype in particular, has been previously described
(32). In adult patients with RA, CD4 T cells are
retained in the synovium, while CD8 T cells accumu-
late in the SF (33). Unlike the findings in patients with
type I diabetes, in whom CD8 T cells participate in the
destruction of pancreatic islet cells through specific lysis
(34), no clear role for the cytotoxic lymphocyte has yet
been demonstrated in the joint. Furthermore, synovial T
cells have been reported to be anergic ex vivo (35). Since
the level of turnover of synovial T cells did not differ
between subsets, our results support a model in which
the distribution of CD4 and CD8 T cells in the joint is a
reflection of the cytokine and chemokine milieu attract-
ing migration into the joint. Our results also support a
role for CCL5 (RANTES), which was demonstrated to
influence migration of CD8 T cells over CD4 T cells and
to be a predictor of the extension of oligoarticular JIA.
Therefore, although we cannot exclude the possibility of
a distinct role for CD8 T cells, a low CD4:CD8 ratio may
simply be an indirect measure of the effects of chemo-
kines on migration to the joint. Once in the joint, CD8 T
cells, and not CD4 T cells, produce CCL5 (26). This may
therefore provide a positive feedback loop enhancing
the selective migration of CD8 T cells.
Further support for a role of CCL5 derives from
the finding of a higher expression of TPSAB1, the gene
encoding -tryptase, in patients with persistent disease.
Beta-tryptase is a serine protease whose proarthritic
potential (demonstrated in mice) (36) is thought to be
due to its similarity to other matrix-destroying protein-
ases (37). However, Pang et al recently described a role
for -tryptase in the abrogation of CCL5 by specific
cleavage (38). Thus, this protein could play a role in
limiting chemokine activity by cleavage within the joint.
The profile of differentially expressed genes be-
tween patients whose mild disease persisted and those
whose disease became worse gives a snapshot of early
disease in which the shift toward proinflammatory ver-
sus antiinflammatory mechanisms has already been
made. A significant subset of the genes expressed in the
extended-to-be disease group overlapped with genes
expressed in activated macrophages in vitro (29). Differ-
entiation of macrophages, particularly of the M1 type, is
associated with greatly increased transcriptional and
metabolic activity (29). Since the proportions of
monocyte/macrophage-phenotyped cells did not signifi-
cantly differ in the samples subjected to microarray
analysis, it is possible that the level of activation or
differentiation in these cells was higher in the patients
whose disease would later extend. These macrophage-
associated genes, together with complement and carti-
lage glycoprotein 39, form a group of genes that are
predictive of disease extension and link oligoarticular
JIA to more severe forms of JIA, such as the polyartic-
ular and systemic-onset forms (39–41).
Genes that were more highly expressed in chil-
dren with persistent oligoarticular JIA revealed factors
with roles in immune regulation that were not previously
examined in JIA. Adiponectin and the vasoactive intes-
tinal peptide receptor both have antiinflammatory sig-
naling properties that are correlated with less severe RA
and with the amelioration of collagen-induced arthritis
in mice (42–46). Our results implicate new pathways to
disease control that may act independently or in concert
with the previously characterized activity of Treg cells. It
was interesting that neither the Treg cell proportions nor
the FoxP3 protein levels in these cells were predictive of
the outcome in this study. However, the association of
SMAD3 with a more favorable outcome is consistent
with its role as a transducer of the transforming growth
factor  (TGF) signal that leads to FoxP3 expression
and regulatory function (47). Similarly, proportions of
Th17 cells were not predictive in this patient group, and
RORC, the transcription factor associated with Th17
cell development, was more highly expressed in the
patients whose disease persisted. Similar to TGF, the
transcription factor RUNX1 has been linked to both
FoxP3 and RORC transcriptional activity (48,49).
RUNX1 and SMAD3, which were associated with dis-
ease extension and disease persistence, respectively,
could therefore be functioning to modulate the transcrip-
tome to tip the balance in favor of heightened inflamma-
tion or a more quiescent environment in the joint.
A possible limitation of using synovial cells for
this analysis is that not all patients will have an SF
aspirate available or may not have undergone synovial
aspiration. However, previous studies comparing gene
expression profiling on peripheral blood cells in JIA
have been unable to distinguish between persistent
oligoarticular JIA and oligoarticular JIA that has al-
ready extended (at that time, referred to as polyarticular
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previous findings indicating differences in the SF be-
tween those with persistent oligoarticular JIA and those
with extended disease, we chose to focus on synovial
cells herein. Findings in other studies that have at-
tempted to identify clinical predictors of disease exten-
sion have suggested that the pattern and number of
affected joints at presentation may be useful for predic-
tion. All of the subjects in this study had knee arthritis,
and therefore, they may not represent a fully represen-
tative cross-section of all types of oligoarticular JIA. In
addition, the study size may have been too small to
detect such a predictive value of these clinical factors. In
our analysis in this group, adding such clinical indices
into the model did not improve our ability to predict
those whose disease would extend. In addition, we
focused on outcome at only 1 year, since this study
aimed to uncover predictors of early extension; it is, of
course, possible that the children in the persistent oligo-
articular JIA group in this study might later experience
an extension of arthritis into 5 or more joints. However,
we suggest that predictors of early extension may well be
useful clinical/prognostic tools in the management of
oligoarticular JIA.
Thus, in this study, we have proposed new ways to
identify children at risk of developing a more severe
form of JIA after an initial diagnosis of mild disease, by
examining transcript and protein levels in the SF. These
findings now deserve further investigation in prospective
studies. Although it is unlikely that any single measure-
ment will individually discriminate between these 2
outcomes, it is possible that a biomarker set of strong
predictors could provide a valuable prognostic tool for
this type of childhood arthritis.
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